Review
Oncology
Lei Hao, Zhuoli Tian, Shanli Li, Kemin Yan, Yan Xue
Summary: This report presents three cases of MRONJ in patients receiving bisphosphonates therapy, who underwent necrotic bone resection and L-PRF treatment with no recurrence or adverse events observed after 6 months of follow-up. This suggests that the combination of necrotic bone resection and L-PRF may be an effective alternative treatment for advanced MRONJ cases.
Review
Oncology
Terry L. Ng, Megan M. Tu, Mohammed F. K. Ibrahim, Bassam Basulaiman, Sharon F. McGee, Amirrtha Srikanthan, Ricardo Fernandes, Lisa Vandermeer, Carol Stober, Marta Sienkiewicz, Ahwon Jeong, Deanna Saunders, Arif A. Awan, Brian Hutton, Mark J. Clemons
Summary: A systematic review was conducted on the risk-benefit of using bone-modifying agents (BMAs) for more than 2 years in breast cancer or castrate-resistant prostate cancer patients. The evidence suggests that BMAs may reduce skeletal-related event rates but have limited impact on quality of life, with potential risks of osteonecrosis of the jaw and other toxicities. Prospective randomized studies with a focus on quality of life are needed to better inform the use of BMAs beyond 2 years.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Multidisciplinary Sciences
Audrey E. Lord, Liang Zhang, Jamie E. Erickson, Shaughn Bryant, Christine M. Nelson, Stephanie M. Gaudette, Lucy A. Phillips, Annette J. Schwartz Sterman, Soumya Mitra
Summary: In this study, in vivo micro-computed tomography (mu CT) was used alongside traditional measurement methods to evaluate the effectiveness of prednisolone treatment in a murine model of collagen-induced arthritis. The findings demonstrated that prednisolone treatment restored bone volume and reduced inflammation, as confirmed by in vivo and ex vivo mu CT imaging, as well as histopathology.
SCIENTIFIC REPORTS
(2022)
Review
Endocrinology & Metabolism
Y. Wu, F. Wang, Z. Zhang
Summary: Bisphosphonates are safe and beneficial for maintaining bone mineral density in patients with spinal cord injury, reducing the risk of bone loss.
OSTEOPOROSIS INTERNATIONAL
(2021)
Article
Endocrinology & Metabolism
Erik Fink Eriksen, Maziar Shabestari, Asim Ghouri, Philip G. Conaghan
Summary: Osteoarthritis is a prevalent disease globally with no effective disease modifying drug developed yet. Bisphosphonates have shown potential as a treatment for OA in in vitro and animal studies, but human studies have been disappointing with limited short-term efficacy demonstrated in clinical trials.
Review
Endocrinology & Metabolism
Shunji Takahashi
Summary: Breast cancer and prostate cancer, which are dependent on sex hormones, are often treated with hormone-suppression therapies. However, these therapies can lead to bone loss and osteoporosis. Current evidence shows that endocrine therapy decreases bone mineral density, aromatase inhibitors increase fractures in breast cancer patients, and androgen deprivation therapy is likely to increase fractures in prostate cancer patients. Administering bisphosphonates, denosumab, and SERMs can increase bone mass in patients on hormone therapy for breast and prostate cancer, and they also reduce the risk of fractures.
JOURNAL OF BONE AND MINERAL METABOLISM
(2023)
Review
Cell Biology
Jozef Ban, Valerie Fock, Dave N. T. Aryee, Heinrich Kovar
Summary: Bone and bone marrow are common metastatic sites of cancer, often associated with poor disease prognosis. Current therapeutic options for bone metastases are limited and mainly palliative. Further research into the molecular pathways of bone metastasis is needed to develop more successful treatments for improved patient outcomes.
Article
Biochemistry & Molecular Biology
Marissa Chatterjee, Fernanda Faot, Cassia Correa, Jente Kerckhofs, Katleen Vandamme
Summary: The study revealed that ovariectomy-induced osteoporosis only affects specific jaw bone regions, which can be prevented by bisphosphonate treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Dentistry, Oral Surgery & Medicine
K. C. Kumar, Bishwa Prakash Bhattarai, Shilu Shrestha, Bijaya Shrestha, Manash Shrestha
Summary: Locally delivered bisphosphonates have a positive effect on alveolar bone regeneration in patients with periodontitis and can reduce marginal bone loss after dental implant placement.
JOURNAL OF EVIDENCE-BASED DENTAL PRACTICE
(2021)
Article
Multidisciplinary Sciences
Abdul-Amir Yassine, William C. Y. Lo, Tina Saeidi, Dallis Ferguson, Cari M. Whyne, Margarete K. Akens, Vaughn Betz, Lothar Lilge
Summary: Spinal metastases commonly occur in advanced breast, lung, or prostate cancer, and treatment options include systemic and localized therapies. Photodynamic therapy (PDT) using non-toxic photosensitizer drugs has shown promise as a minimally invasive alternative, but predictive algorithms are needed to optimize tumor treatment and minimize spinal cord damage risk. PDT simulation using different light diffuser configurations and wavelengths showed potential for tumor treatment with limited spinal cord damage, but further preclinical studies are needed to assess long-term functional outcomes before clinical trials can be considered.
SCIENTIFIC REPORTS
(2021)
Article
Endocrinology & Metabolism
Gregory A. A. Kline, Suzanne N. N. Morin, Lisa M. M. Lix, William D. D. Leslie
Summary: Based on the FLEX study in 2006, a 5-year course of bisphosphonate therapy was found to be sufficient for most women. However, despite the increased risk of atypical femoral fractures associated with long-term use, up to one-third of patients continued to receive bisphosphonate therapy for over 10 years after 2010.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Article
Plant Sciences
Ho Jun Kang, Nicholas Chargo, Soumya Chennupati, Kerri Neugebauer, Jae Youl Cho, Robert Quinn, Laura R. McCabe, Narayanan Parameswaran
Summary: This study aimed to test the effect of Korean Red Ginseng extract on bone and gut health using an antibiotics-induced dysbiosis-induced bone loss model in mice. The results showed that the extract can prevent antibiotics-induced bone loss and restore the diversity of gut microbiota and intestinal permeability.
JOURNAL OF GINSENG RESEARCH
(2023)
Review
Oncology
Esmeralda Garcia-Torralba, Francesca Spada, Kok Haw Jonathan Lim, Timothy Jacobs, Jorge Barriuso, Was Mansoor, Mairead G. McNamara, Richard A. Hubner, Prakash Manoharan, Nicola Fazio, Juan W. Valle, Angela Lamarca
Summary: The systematic review and meta-analysis revealed that BM prevalence in NENs patients is 18.4%, with mainly osteoblastic and multifocal characteristics, pain being the most common symptom. Various treatment modalities are used with limited evidence available for their efficacy.
CANCER TREATMENT REVIEWS
(2021)
Article
Biochemistry & Molecular Biology
Yuh-Ching Gau, Tsung-Jang Yeh, Chin-Mu Hsu, Samuel Yien Hsiao, Hui-Hua Hsiao
Summary: Multiple myeloma-related bone disease (MBD) is caused by an imbalance in the bone-remodeling process and involves various signaling pathways and molecules. Bisphosphonate and denosumab are currently the standard treatments, while novel bone-modifying therapies are being explored.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Dentistry, Oral Surgery & Medicine
Winston Adam Camargo, Jan Willem Hoekstra, John A. Jansen, Jeroen J. J. P. van den Beucken
Summary: In this study, the effect of alendronate (ALN) treatment on bone defect regeneration in osteoporotic rats was evaluated. The results showed that oral administration of ALN can enhance bone formation in the defects, increasing it to 10 times compared to the non-treated group. Additionally, Bio-Oss(R) was found to be an effective bone substitute, promoting bone formation in both healthy and osteoporotic conditions. The study highlights the beneficial effects of oral ALN in mitigating the adverse effects of osteoporosis on bone defect regeneration.
CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH
(2023)